FDA, Advisers Mull "Polypill" for Patients With Cardiovascular Disease
Wed, 22 Oct 2014 00:00:00 -0400
concept of combination therapy packaged in a so-called polypill for patients
with cardiovascular disease received a mostly favorable reception in September
from FDA officials and agency advisers.
Nintedanib Approved as Idiopathic Pulmonary Fibrosis Treatment
Mon, 20 Oct 2014 00:00:00 -0400
FDA last week approved the marketing of nintedanib, or Ofev, for the treatment of idiopathic pulmonary fibrosis.
EV-D68 Outbreak Taxes Respiratory Medication Supply
Fri, 17 Oct 2014 00:00:00 -0400
Before their hospital became the first to report what evolved into a nationwide outbreak of severe enterovirus D-68 (EV-D68) infections, the pharmacy staff at Children's Mercy Hospital and Clinics in Kansas City, Missouri, noticed some unexpected things happening with their drug inventory.
Pirfenidone Approved for Treatment of Idiopathic Pulmonary Fibrosis
Thu, 16 Oct 2014 00:00:00 -0400
FDA on October 15 approved the marketing of pirfenidone, or Esbriet, for the treatment of idiopathic pulmonary fibrosis.
Ledipasvir--Sofosbuvir Approved for Chronic Hepatitis C Infection
Tue, 14 Oct 2014 00:00:00 -0400
Gilead Sciences on October 10 announced
the approval of Harvoni, a two-drug combination product for the treatment of
chronic hepatitis C virus (HCV) genotype 1 infection in adults.